Publications in connection with SSPI:

  1. MacEachern, L., Kermanshahi-pour, A., Mirmehrabi, M. "Transformation under pressure: Discovery of a novel crystalline form of anthelmintic drug Praziquantel using high-pressure supercritical carbon dioxide", International Journal of Pharmaceutics, 619 (2022) 121723, https://authors.elsevier.com/c/1eu~M1M49kXF5U.
  2. Ahmadi S., Mondal P.K., Wu Y., Gong W., Mirmehrabi M., Rohani S., "Virtual Multicomponent Crystal Screening: Hydrogen Bonding Revisited", Cryst. Growth Des., 2021, 21, 10, 5862–5872.
  3. Samipillai M., Mirmehrabi M., Rohani S., 2021, "Co-amorphous solids of dasatinib and olanzapine by saccharin with promising physicochemical properties", Journal of Drug Delivery Science and Technology, https://www.sciencedirect.com/science/article/abs/pii/S1773224721004809.
  4. Mondal P.K., Mirmehrabi M., Rohani S., 2021, “Insight into the Formation of Heteromolecular Hydrogen Bonds between Dasatinib and GRAS Molecules”, Organic Process Research & Development, ACS, https://doi.org/10.1021/acs.oprd.0c00549.
  5. Ahmadi S., Mondal P.K., Mirmehrabi M., Rohani S., 2021, "Desolvation of dasatinib methanolate: An improved anhydrous polymorph", CrystEngComm, https://doi.org/10.1039/D1CE00337B.
  6. MacEachern, L., Walwyn-Venugopal, R., Kermanshahi-pour, A., Mirmehrabi, M. "Ternary Phase Diagram Development and Production of Niclosamide-Urea Co-Crystal by Spray Drying."  Journal of Pharmaceutical Sciences, 10.1016/j.xphs.2020.11.036. Advance online publication. https://doi.org/10.1016/j.xphs.2020.11.036
  7. MacEachern, L., Kermanshahi-pour, A., Mirmehrabi, M. “Supercritical Carbon Dioxide for Pharmaceutical Co-Crystal Production”, Crystal Growth and Design., 2020, 20(9), 6226-6244.
  8. Kermanshahi pour A., Mirmehrabi M., Brar, S. K., 2020. “A novel process for isolation and purification of polyunsaturated fatty acids from a thraustochytrid”, Algal Research, 46, 101806.
  9. Caplette J., Frigo T., Jozwiakowski M., Shea H., Mirmehrabi M., Müller P., 2017. "Characterization of new crystalline forms of hydroxyprogesterone caproate", International Journal of Pharmaceutics, 527 (1), 42-51.
  10. Kermanshahi pour A., MacEachern L., Mirmehrabi M., 2017. “A novel process for preparation of fatty acid oil mixture in solid form”, Food Chemistry, 229, 50-56.

 

Publications of our team members prior to joining SSPI:

  1. Samipillai, M.; Rohani, S. “The Role of Higher Coformer Stoichiometry Ratio in Pharmaceutical Cocrystals for Improving Their Solid-State Properties: The Cocrystals of Progesterone and 4-hydroxybenzoic acid." J. Cryst. Growth 2019, 507, 270-282.
  2. Samipillai, M.; Bhatt, N.; Bhatt, P.; Govender, T.; Kruger, H.G.; Maguire, G.M. “N-valine-2-(3,5-dimethy-1,1-dioxido-2H-1,2,6-thiadiazin-4-yl)benzamide: Synthesis, Spectroscopy, X-ray structure and Hirshfeld surface analysis”. J. Chem. Crystallogr. 2019, 49, 65-71.
  3. Brasil, E.; Samipillai, M.; Govender, T.; Kruger, H. G.; Naicker, T. “Crystal structure of (E)-2-(4-cyanophenyl) ethenesulfonyl fluoride, C9H6FNO2S", Z Krist-New Cryst. St. 2019 234 (3), 441-442.
  4. Govender, K. B.; Samipillai, M.; Govender, T.; Kruger, H. G.; Naicker, T. “Crystal structure of 2-(bis (3, 5-dimethylphenyl)((methyldiphenylsilyl) oxy) methyl) pyrrolidine, C34H39NOSi", Z Krist-New Cryst. St. 2019 234 (3), 413-415.
  5. Peters, B.; Razuwika, R; Samipillai, M.; Arvidsson, P. I.; Kruger, H. G.; Govender, T.; Naicker, T. “An unexpected re-arrangement of the antibiotic carbapenem core to new 1,4 diazepin-5-one scaffolds.” RSC Adv., 2018, 8, 190-193.
  6. Naicker, T. Brasil, E.; Samipillai, M.; Govender, T.; Baijnath, S. “Crystal structure of 2-(4-fluorophenyl)-N-phenyl-2-(phenylamino) ethanesulfonamide–toluene (1/0.5), C23. 5H23FN2O2S”. Z Krist-New Cryst. St. 2018, 234 (1), 169-171
  7. Khumalo, M; Samipillai, M.; Govender, T.; Kruger, H. G.; Naicker, T. “Crystal structure of (E)-2-(4-bromophenyl) ethenesulfonyl fluoride (C8H6BrFO2S)”. Z Krist-New Cryst. St. 2018, 233 (5), 793-794.
  8. Govender, K.; Samipillai, M.; Govender, T.; Kruger, H. G.; Naicker, T. “Synthesis, charecterization and crystal structure of methyl 1-(2-(fluorosulfonyl) ethyl)-2-oxocyclopentanecarboxylate, C9H13FO5S.” Z Krist-New Cryst. St. 2017, 232(4), 697-698. 
  9. Makam, P.; Samipillai, M.; Govender, T.; Kruger, H. G.; Naicker, T. “Synthesis and crystal strcuture of tert-Butyl phenylsulfinylcarbamate, C11H15NO3S”. Z Krist-New Cryst. St. 2017, 232(4), 577-578.
  10. Samipillai, M.; Govender, T.; Kruger, H. G.; Naicker, T. “Crystal structure of (S)-benzyl 3-(benzylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate.” Z Krist-New Cryst. St. 2017, 232(3), 425-426.
  11. Samipillai, M.; Govender, T.; Kruger, H.G.; Maguire, G.M. “Crystal structure of 4,10,16,22-Tetrahydroxy-6,12,18,24-tetramethoxy-2,8,14,20-tetraethylphenylresorcin[4]arene and ethyl acetate”. Z Krist-New Cryst. St. 2017, 232(2), 305-307.
  12. Patel, R. C.; Samipillai, M.; Govender, T.; Kruger, H.G.; Friedrich, B. H.; Maguire, G.M. Crystal structure of 5,11,17,23-Tetra(tert-butyl)-25,26,27,28-tetrahexoxycalix[4]arene.” Z Krist-New Cryst. St. 2017, 232(3), 397-402.
  13. Samipillai, M.; Govender, T.; Kruger, H. G.; Naicker, T. Crystal structure of 5-acetyl-3-(3-fluoro-4-morpholinophenyl) oxazolidin-2-one.” Z Krist-New Cryst. St. 2017, 232(3), 427-428.
  14. 17. Samipillai, M.; Bhatt, N; Kruger, H. G.; Govender, T.; Naicker, T. “Diverse supramolecular arrangement of substituted oxopyrrolidine analogues influenced by weak intermolecular interactions (C-H…O/C-H…π/H…H).” J. Mol. Struct. 2016, 1122, 37-47.
  15. Makhathini, S.; Samipillai, M.; Govender, T.; Naicker, T. “Crystal structure of 1-tert-butyl 2-ethyl 2-((tert-butoxycarbonylamino)(4-fluorophenyl)methyl)-3-oxopyrrolidine-1,2-dicarboxylate.” Z Krist-New Cryst. St. 2016, 231(3), 819-821.
  16. Makhathini, S.; Samipillai, M.; Govender, T.; Naicker, T. “Crystal structure of 1-tert-butyl 2-ethyl 2-((tert-butoxycarbonylamino)(phenyl)methyl)-3-oxopyrrolidine-1,2-dicarboxylate.” Z Krist-New Cryst. St. 2016, 231(3), 725-727.
  17. Bhatt, N.; Samipillai, M.; Bhatt, P.; Govender, T.; Kruger, H.G.; Maguire, G.M. “Crystal structure of Butyl 2-(3,5-dimethyl-1,1-dioxido-2H-1,2,6-thiadiazin-4-yl)benzoate.” Z Krist-New Cryst. St. 2016, 231(2), 373–374.
  18. Bhatt, N.; Samipillai, M.; Bhatt, P.; Govender, T.; Kruger, H.G.; Maguire, G.M. “Crystal structure od ethyl 2-(2-nitro-1-phenylethyl)-4-oxopyrrolidine-2-carboxylate hydrochloride.” Z Krist-New Cryst. St. 2016, 231(1), 43-45.
  19. Samipillai, M.; Batisai, E.; Nassimbeni, L. R.; Weber E. “Separation of Lutidines by Enclathrarion.” CrystEngComm 2015, 17, 8332-8338.
  20. Samipillai, M.*; Nassimbeni, L. R.; Weber, E. “Pyridine and Morpholine Inclusion by a Binaphthyl Host.” J Chem. Crystallogr. 2014, 44, 293–300 (*corresponding author)
  21. MacEachern L., A. Sylvester, A. Flynn, A. Rahmani, and M. R. Morrow, Langmuir, 2013. "Dependence of Bicellar System Phase Behavior and Dynamics on Anionic Lipid Concentration", 29 (11) 3688 - 3699.
  22. Nassimbeni, L. R.; Samipillai, M.; Su, H.; Weberb, E. “Inclusion of picolines by a substituted binaphthyl diol host: selectivity and structure.” RSC Advances 2013, 3, 25758-25764.
  23. Chitnis, S., MacDonald, E., Burford, N., Werner-Zwanziger, U., MacDonald, R., 2012. “P_P Menschutkin preparation of prototypical phosphinophosphonium Salts” Chem. Commun., 48, 7359-7361. 
  24. 25. Cheng, P.-S.; Samipillai, M.; Zang, S.-Q.; Gao, G.-G.; Thomas C. W. Mak. “Argentophilic Infinite Chain, Column, and Layer Structures Assembled with the Multinuclear Silver(I)−Phenylethynide Supramolecular Synthon”. Crystal Growth & Design 2012, 12, 4519−4529.
  25. Arunachalam, M; Chakraborty, S; Samipillai, M. Ghosh, P. “Anion Assisted Formation of Discrete Homodimeric and Heterotetrameric Assemblies by Benzene Based Protonated Heteroaryl Receptors.” Crystal Growth & Design 2012, 12, 2097−2108.
  26. 27. Samipillai, M.; Arunachalam, M.; Ghosh, P. “Binding of Polyatomic Anions with Protonated Ureido-pyridyl Ligands.” Crystal Growth & Design 2011, 11, 1642-1650.
  27. L'Heureux, A., F. Beaulieu, C. Bennett, D.R. Bill, S. Clayton, F. La Flamme, M. Mirmehrabi, S. Tadayon, D. Tovell and M. Couturier, 2010. “Aminodifluorosulfinium Salts: Selective Fluorination Reagents with Enhanced Thermal Stability and Ease of Handling”, Journal of Organic Chemistry, 75(10), 3401-3411.
  28. 8. Samipillai, M.; Braga, D.; Grepioni, F.; Lampronti, G. I. “Mechanochemical preparation of co-crystals of 1, 4-diazabicyclo [2.2.2] octane with aromatic polycarboxylic acids: co-crystals obtained through solid state grinding as well as solution crystallization method.” CrystEngComm 2010, 12, 2107-2112.
  29. Samipillai, M.; Suresh, E.; Pedireddi, V. R. “Molecules to supermolecules and self-assembly: A study of some cocrystals of cyanuric Acid.” Teterahedron Lett. 2008, 49, 3666-3671.
  30. Trifkovic M., S. Rohani, and M. Mirmehrabi, 2007. “Polymorphic Generation through Solvent Selection: Ranitidine Hydrochloride”, Organic Process Research & Development, 11(1), 138-143.
  31. Samipillai, M.; Shimpi, M. R.; Pedireddi, V. R. “Novel supramolecular assemblies of coordination polymers of Zn(II) and bis(4-nitrophenyl)phosphoric acid with some aza-donor compounds.” Crystal Growth & Design 2007, 7, 1791-1996.
  32. Mirmehrabi M., S. Rohani, K.S.K Murthy and B. Radatus, 2006. “Polymorphic Behavior and Crystal Habit of an Anti-Viral/HIV Drug: Stavudine”, Crystal Growth and Design (American Chemical Society), 6(1), 141-149.
  33. Mirmehrabi M., Rohani S., and L. Perry, 2006. “Predicting Solubilities of Pharmaceutical Compounds”, Chemical Engineering Progress, 102(12), 6, 20-21.
  34. Mirmehrabi M., S. Rohani and L. Perry, 2006. “Thermodynamic Modeling of Activity Coefficient and Prediction of Solubility: Part 1. Predictive Models”, Journal of Pharmaceutical Sciences, 95(4), 790-797.
  35. Mirmehrabi M., S. Rohani and L. Perry, 2006. “Thermodynamic Modeling of Activity Coefficient and Prediction of Solubility: Part 2. Semi-Predictive or Semi-Empirical Models”, Journal of Pharmaceutical Sciences, 95(4), 798-809.
  36. Mirmehrabi, M., S. Rohani, M. C. Jennings, 2005. “Stavudine”, Acta Crystallographica, Section C: Crystal Structure Communications, C61(12), 695-698.
  37. Mirmehrabi M. and S. Rohani, 2004. “An Approach to Solvent Screening for Crystallization of Polymorphic Pharmaceuticals and Fine Chemicals”, Journal of Pharmaceutical Sciences, 94 (7), 1560-1576.
  38. Mirmehrabi M., S. Rohani, K.S.K Murthy and B. Radatus, 2004. “Improving the Filterability and Solid Density of Ranitidine Hydrochloride Form 1”, Journal of Pharmaceutical Sciences, 93 (7), 1692-1700.
  39. Mirmehrabi M., S. Rohani, K.S.K Murthy and B. Radatus, 2004. “Solubility, Dissolution Rate and Phase Transition Studies of Ranitidine Hydrochloride Tautomeric Forms”, International Journal of Pharmaceutics, 282(1-2), 73-85.
  40. Mirmehrabi M., S. Rohani, K.S.K. Murthy and B. Radatus, 2004. “Characterization of Tautomeric Forms of Ranitidine Hydrochloride: Thermal Analysis, Solid-State NMR, X-ray”, Journal of Crystal Growth, 260, 517-526.
  41. Mirmehrabi M. and S. Rohani, 2004. “Measurement and Prediction of the Solubility of Stearic Acid Polymorphs by the UNIQUAC Equation”, Canadian Journal of Chemical Engineering, 82 (2), 335-342.

Patents/patent applications in connection with SSPI:

  1. Waetzig Joshua D., Mar Brenton., Heinrich Brian., Wilkie Gordon., MacEachern Lauren., 2021. “Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-F-][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making”, US Patent 20210147433
  2. Mirmehrabi M., 2020. “Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate", US Patent 10556922
  3. Mirmehrabi M., Jonas M., Batchu P.K., 2019, "Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile", WO Patent 2020010068A1
  4. Reddy J.P., Mirmehrabi M., Kota M., Dash U., 2019. “Process of making somatostatin modulators”, US Patent 10464918
  5. Sizemore J. P., Guo L., Mirmehrabi M., Su Y., 2019. "Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide", WO Patent 2019104134A1

 

Patents/patent applications of our team members prior to joining SSPI:

  1. Mollard P., Cornell C.R., Wesson K.E., Giannousis P., Suchit S., Mirmehrabi M., 2019. “Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide”, US Patent 10251847
  2. Matharu S., Heinrich B., Singh A., Mirmehrabi M., 2018. “Process of preparing low ABUK oxymorphone hydrochloride”, US Patent 9918979B2
  3. Andres P., Datar Y., Gadiraju R., Kowalczyk B. A., Kuklis G. C., Mirmehrabi M., Paschalides N., 2017. “Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof”, EP Patent 2914599B1
  4. Heinrich B.W., Gou D.M., Mirmehrabi M., Paul B., Coughlin D.J. 2017. “Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same”, US Patent 9815844B2
  5. Singidi R.K.R., Gududuru V., Mirmehrabi M., Thompson K.E., Tigyi G.J., Yates C.R., Strobos J., 2017. “Crystalline salts of (Z)-O-octadec-9-en-1-yl O,O-dihydrogen phosphorothioate”, US Patent 15429972
  6. Singh A., Mirmehrabi M., 2015. “Crystalline forms of silodosin”, US Patent App. 20160194281A1
  7. Singh A., Mirmehrabi M., 2015. “Forms of oxymorphone hydrochloride”, US Patent 9062063 B1
  8. Paschalidis N., Mirmehrabi M., 2015. “Crystalline forms of morphine sulfate”,US Patent 9145420B1
  9. Mollard P., Giannousis P., Mirmehrabi M., Alite H., Singh A., 2014. “Methods for chiral resolution of trolox”, US Patent App. 20180002247A1
  10. Brittain J., Stanley C., Kolchinski A., Mirmehrabi M., Bell D., 2013. “Synthesis and formulations of porphyrin compounds”, US Patent App. 20160333019A1
  11. Lu Q., Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M, 2012. “Preparation of maleate salt of neratininb and its use”, EP Patent 2537843
  12. Lu Q., Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M, 2012. “Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof”, US Patent 20120289545
  13. Lu Q., Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M, 2011. “Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof”, US Patent App. 13/181,37
  14. Chew W, Wang Z, Nencini A, Zanaletti R, Cheal G, Bertrand M, Potoski J, Mirmehrabi M, 2009. “Synthesis of pyrazoles”, WO Patent 2009091832
  15. Lu Q., Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M, 2012. “Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof”, US Patent 20120289545
  16. Lu Q., Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M, 2011. “Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof”, US Patent App. 13/181,37
  17. Mirmehrabi M, Nencini A, Zanaletti R, Tadayon A, Deshmukh S, 2009, “Compound forms and uses thereof”, WO Patent 2009091831
  18. Alimardanov AR, Krishnan L, Zhou M, Wang TZ, Ren J, Considine JL, WU CC, Brazzillo J, Raveendranath P, Sutherland KW, Mirmehrabi M, Deshmukh S, 2009. “Synthesis of pyrrolidine compounds", EP Patent 2,074,087
  19. Krishnan MK, Ghorab M, Carson RW, Hasan S, Nagi A, Tadayon A, Iera S, Mirmehrabi M, 2009. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benoxazol-5-ol and pharmaceutical formulations thereof”, EP Patent 2064195
  20. Alimardanov AR, Sutherland KW, Mirmehrabi M, Deshmukh S, Krishnan L, Zhou M, Wang TZ, Ren J, Considine JL, Wu CC, Brazzillo J, Raveendranath P, 2009, “Synthesis of pyrrolidine compounds”, EP Patent 2468724
  21. Lu Q, Ku M, Chew W, Cheal G, Hadfield A, Mirmehrabi M, 2009. “Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy) anilino]-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof”, WO Patent 2009052264
  22. Mirmehrabi M, Tadayon A, Deshmukh S, Nencini A, Zanaletti R,2009. ” Compound forms and uses thereof”, US Patent App. 12/353,891
  23. Chew W, Wang Z, Cheal G, Bertrand M, Potoski J, Mirmehrabi M, Nencini A, Zanaletti R, 2009. “Synthesis of pyrazoles”, US Patent App. 12/353,896
  24. Mirmehrabi M, Niu Y, Tadayon A, Deshmukh S, Ku MS, 2008, “Synthesis and characterization of polymorph form II of 4-(2-(4, 4-dimethyl-2-oxooxazolidin-3-YL) thiazol-4-YL) benzonitrile”, US Patent App. 12/075,228
  25. Mirmehrabi M, Tadayon A, Deshmukh S, 2008. “Synthesis and characterization of polymorph form III 4-(2-(4, 4-dimethyl-2-oxooxazolidin-3-yl) thiazol-4-yl) benzonitrile”, US Patent App. 12/075,248
  26. Deshmukh S., Mirmehrabi M, 2008. “Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry”. EP Patent 1957964
  27. Deshmukh S, Mirmehrabi M, 2008. “Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry”. WO Patent 2007067566
  28. Mirmehrabi M, Niu Y, Tadayon A, Deshmukh S, Ku MS, 2008. “Synthesis and characterization of polymorph form III 4-(2-(4, 4-dimethyl-2-oxooxazolidin-3-yl) thiazol-4-yl) benzonitrile”, WO Patent 2008112498
  29. Mirmehrabi M, Tadayon A, Deshmukh S, 2008. “Synthesis and characterization of polymorph form III 4-(2-(4, 4-dimethyl-2-oxooxazolidin-3-yl) thiazol-4-yl) benzonitrile”, WO Patent 2008112495
  30. Deshmukh S, Ali K, Diorio CR, Ehrnsperger EC, Fawzi MB, Shah SM, Mirmehrabi M, 2008. “Glucuronate salt of a piperazine compound”, EP Patent 1940830
  31. Mirmehrabi M, Megati S, Tadayon A, Deshmukh S, 2008. “Crystalline forms and polymorphs of n-(3-(dimethylamino) propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as succinate salts”, US Patent App. 12/105,443
  32. Mirmehrabi M, Tadayon A, Deshmukh S, 2008. “Crystalline polymorphs of n-(3-(dimethylamino) propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts”, US Patent App. 12/105,520
  33. Mirmehrabi M, Tadayon A, Deshmukh S, 2008, “Crystalline polymorphs of n-(3-(dimethylamino) propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as acetate salts” US Patent App. 12/105,507
  34. Mirmehrabi M, Megati S, Tadayon A, Deshmukh S, 2008. “Crystalline forms and polymorphs of n-(3-(dimethylamino) propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as pharmaceutically acceptable salts”, US Patent App. 12/105,567
  35. Papamichelakis M, Lunetta JF, Lankau M, Richard L, Kendall C, Saraiva MC, Wen X, Mirmehrabi M, Paquet V, Daigneault S, Zhang P, 2008, “Methods for the preparation of hydroxy-substituted aryl sulfamide compounds”, US Patent App. 12/332,400
  36. Bernatchez M, Chew W, Daigneault S, Palus E, Mirmehrabi M, Bouchard L, 2008. ”Tigecycline and methods of preparing intermediates”, US Patent App. 12/251,488
  37. Krishnan M, Ghorab M, Carson R, Hasan S, Nagi A, Tadayon A, Iera S, Mirmehrabi M, 2008. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol and pharmaceutical formulations thereof”, WO Patent 2008064217
  38. Mirmehrabi M, Considine JL, Niu Y, Tadayon A, Deshmukh S, Liang JQ, Wu Y, 2008.“Polymorphs, solvates, and hydrate of 5-(4'-fluoro-2'-oxo-1', 2'-dihydrospiro [cyclopropane-1, 3'-indol]-5'-yl)-1-methyl-1h-pyrrole-2-carbonitrile”, US Patent App. 12/138,852
  39. Deshmukh S, Ali K, Diorio CR, Ehrnsperger EC, Fawzi MB, Shah SM, Mirmehrabi M, 2007. “Glucuronate salt of a piperazine compound”, WO Patent 2007033191
  40. Mirmehrabi M, Yu Q, Tadayon A, Tesconi M, Xu Y, 2007. ”Crystal forms of (S)-(8 (2, 6-dichlorophenyl)-6-fluoro-2, 3-dihydro benzo [b][1, 4] dioxin-2-yl) methanamine hydrochloride salt”, US Patent App. 11/787,633
  41. Tadayon A, Ierq S, Mirmehrabi M, 2007. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol”, US Patent App. 11/943,102
  42. Tadayon A, Ierq S, Mirmehrabi M, 2007. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol“, US Patent App. 11/942,941
  43. Tadayon A, Ierq S, Mirmehrabi M, 2007. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol”, US Patent App. 11/943,076
  44. Tadayon A, Ierq S, Mirmehrabi M, 2007. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol”,US Patent App. 11/942,897

Presentations in connection with SSPI:

  1. Kermanshahi pour A., MacEachern L., Mirmehrabi M., 2018. “A Novel Process for Preparation of Fatty Acid Oil Mixture in Solid Form”, Gordon Research Conference- Crystal Engineering.

  2. MacEachern L., Mirmehrabi M., 2016. "Quantification of Polymorphs in Solid Mixtures by Powder X-Ray Diffraction Using Multivariate Analysis ", AAPS 2016. Poster Presentation.

 

Presentations of our team members prior to joining SSPI:

  1. Mirmehrabi M., 2015 and 2016. “Chemometric Analysis in Solid State Science and Crystallization Engineering”, Mettler Toledo Information Sharing Symposium, Iselin, NJ, and Cambridge, MA, USA.

  2. Mirmehrabi M., 2014. “Particle Engineering for Improved and Consistent Drug Substance Quality”, Boston PBSS Workshop

  3. Batchu P., 2014. "Kinetic Distortion to Thermodynamic Predictions in Crystallizing Triglycerides", AOCS annual meeting and Expo, San Antonio, Texas, (Presented by Dr. Gianfranco Mazzanti).

  4. Batchu P., 2013. "Kinetic Phase Diagrams of Crystallizing Trilaurin-trimyristin Mixtures Using Small Angle X-ray Diffraction", IRM annual general meeting and research day, Halifax, Nova Scotia.

  5. Mirmehrabi M., 2012. “Controlling Oiling Out During Crystallization Process Development”, Mettler Toledo Information Sharing Symposium, Cambridge, MA, USA.

  6. Mirmehrabi M., 2011. “Crystallization and Drying of Hydrates”, Mettler Toledo Information Sharing Symposium, New Brunswick, NJ, USA.

  7. Mirmehrabi M., 2008. “Oiling Out: A Crystallization-Purification Challenge”, 58th Canadian Chemical Engineering Conference, Ottawa, Canada.

  8. Tadayon S., S. Deshmukh, M. Mirmehrabi, J. Liang, Y. Wang, Q. Yu, 2006. “Drying of Pharmaceutical Hydrates”, 13th International Process Development Conference, Rhode Island.

  9. Deshmukh S. and M. Mirmehrabi, 2006. “PAT Tools for Evaluation of Drug Substance Crystallization”, FDA Science, A Century of FDA Science, Washington DC, USA.

  10. Mirmehrabi M. and S. Tadayon, 2006. “Agglomeration of Pharmaceutical Microparticles, the Origin and Implications”, American Institute of Chemical Engineers Conference, Orlando, Florida, USA.

  11. Mirmehrabi M. and S. Rohani, 2006. “Thermodynamic Modeling and Prediction of Solubility of Organic Molecules and Pharmaceuticals”, American Institute of Chemical Engineers Conference, Orlando, Florida, USA.

  12. Mirmehrabi M., S. Tadayon, Q. Yu and S. Deshmukh, 2006. “Thermodynamic Insights into Crystalline Hydrates: a Case Study”, 56th Canadian Chemical Engineering Conference, Sherbrook, Canada.

  13. Rohani S. and Mirmehrabi M., 2005. “Polymorphic Behavior and Crystal Habit of an Anti-Viral/HIV Drug: Stavudine”, American Institute of Chemical Engineers Conference, Cincinnati, OH, USA.

  14. Rohani S. and M. Mirmehrabi, 2004. "Batch Crystallization in Pharmaceutical and Fine Chemicals Industries in Canada", Proceeding of International Technical Forum Inspiring Powder Technology, Tokyo, Japan.

  15. Mirmehrabi M. and S. Rohani, 2004. "Molecular Interactions Between Solvent and Pharmaceutical Compounds in Crystallization of Polymorphic Systems", American Institute of Chemical Engineers Conference, Austin, Texas, USA.

  16. Mirmehrabi M., S. Rohani, K.S.K. Murthy and B. Radatus, 2003. "Tautomeric Polymorphism of Ranitidine Hydrochloride", 53rd Canadian Chemical Engineering Conference, Hamilton, Canada.

  17. Mirmehrabi M. and S. Rohani, 2002. "Control of Polymorphism in Pharmaceutical Products", 52nd Canadian Chemical Engineering Conference, Vancouver, Canada.

  18. Rohani S. and M. Mirmehrabi, 2002. "Solid-Liquid Equilibrium of Stearic Acid Polymorphs in Organic Solvents", 52nd Canadian Chemical Engineering Conference, Vancouver, Canada.

This is a list of downloadable posters developed by the technical team at Solid State Pharma. You will be required to provide your email address to access the posters.

Quantification of Polymorphs in Solid Mixtures by Powder X-Ray Diffraction

Development of screening methodologies for the preparation of amorphous solid dispersions of

Controlling Oiling Out in Crystallization Process Development

A Novel Process for Preparation of Fatty Acid Oil Mixture in Solid Form

Ready to collaborate? Let’s work together

Contact Us

© 2024. All rights reserved. Solid State Pharma Inc. - Developed by Eastwood Design